Despite high R&D spending and cash burn, Moderna aims for breakeven by 2028, driven by new vaccine opportunities. Explore ...

CompanyOverview|NASDAQ:MRNA] The CEO of Moderna Inc. (NASDAQ: MRNA) just purchased $5 million of stock in the open market.

The National Institutes of Health is terminating dozens of studies examining why people are hesitant about vaccines and how to increase uptake. mRNA vaccine research may be on the chopping block, too.

In terms of liquidity and interest, the mean open interest for Moderna options trades today is 3103.07 with a total volume of 1,821.00. In the following chart, we are able to follow the development of ...

Shares of the American pharmaceutical company Moderna (MRNA) climbed over 8% in pre-market trading following strategic ...

Klinger joined the Cambridge, Massachusetts-based pharmaceutical company in 2021, when Moderna's stock was trading at around ...

A German court found Wednesday that American pharmaceutical giant Pfizer and German firm BioNTech violated a patent to make ...

with a breakeven target in 2028. Operating expenses are projected to decrease significantly from $9 billion in 2023 to $5 billion by 2026. Moderna paused its norovirus vaccine study but expects no ...

Moderna CEO Stéphane Bancel received an annual compensation package worth $19.87 million last year, the largest he’s ever received at the company. | While Stéphane Bancel received a ...

The S&P 500 advanced 1.1% on Wednesday, March 5, as the White House announced it would delay tariffs affecting U.S.

We recently compiled a list of the 10 Stocks Lead Wednesday’s Charge, Mirror Broader Gains. In this article, we are going to ...

Barclays 27th Annual Global Healthcare Conference March 11, 2025 1:30 PM ETCompany ParticipantsRose Loughlin - EVP of ...